» Articles » PMID: 29941448

Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone

Overview
Journal Diabetes
Specialty Endocrinology
Date 2018 Jun 27
PMID 29941448
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Previously, we had shown that a vasopeptidase inhibitor drug containing ACE and neprilysin inhibitors was an effective treatment for diabetic vascular and neural complications. However, side effects prevented further development. This led to the development of sacubitril/valsartan, a drug containing angiotensin II receptor blocker and neprilysin inhibitor that we hypothesized would be an effective treatment for diabetic peripheral neuropathy. Using early and late intervention protocols (4 and 12 weeks posthyperglycemia, respectively), type 2 diabetic rats were treated with valsartan or sacubitril/valsartan for 12 weeks followed by an extensive evaluation of vascular and neural end points. The results demonstrated efficacy of sacubitril/valsartan in improving vascular and neural function was superior to valsartan alone. In the early intervention protocol, sacubitril/valsartan treatment was found to slow progression of these deficits and, with late intervention treatment, was found to stimulate restoration of vascular reactivity, motor and sensory nerve conduction velocities, and sensitivity/regeneration of sensory nerves of the skin and cornea in a rat model of type 2 diabetes. These preclinical studies suggest that sacubitril/valsartan may be an effective treatment for diabetic peripheral neuropathy, but additional studies will be needed to investigate these effects further.

Citing Articles

The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights.

Muric M, Srejovic I, Novakovic J, Zivkovic V, Jovic J, Sretenovic J Cardiovasc Drugs Ther. 2025; .

PMID: 39913081 DOI: 10.1007/s10557-025-07675-4.


Sacubitril/Valsartan Combination Partially Improves Cardiac Systolic, but Not Diastolic, Function through β-AR Responsiveness in a Rat Model of Type 2 Diabetes.

Erdogan B, Yesilyurt-Dirican Z, Karaomerlioglu I, Muderrisoglu A, Sevim K, Michel M Int J Mol Sci. 2024; 25(19).

PMID: 39408945 PMC: 11476658. DOI: 10.3390/ijms251910617.


Metabolomic and lipidomic profiling of the spinal cord in type 2 diabetes mellitus rats with painful neuropathy.

Yu Z, Yang J, Jiang Y, Wei M, Lyu Y, Yang D Metab Brain Dis. 2024; 39(6):1117-1130.

PMID: 38980579 PMC: 11349861. DOI: 10.1007/s11011-024-01376-x.


Combination therapy is it in the future for successfully treating peripheral diabetic neuropathy?.

Yorek M Front Endocrinol (Lausanne). 2024; 15:1357859.

PMID: 38812811 PMC: 11133577. DOI: 10.3389/fendo.2024.1357859.


Role of angiotensin receptor-neprilysin inhibitor in diabetic complications.

Liu Y, Lu C, Zheng Y, Zhang Y, Qian L, Li K World J Diabetes. 2024; 15(5):867-875.

PMID: 38766431 PMC: 11099356. DOI: 10.4239/wjd.v15.i5.867.